Nkarta’s Share Slide Highlights the Risks of Over‑Optimistic Biotech Valuations
Nkarta’s stock drop to $1.74 highlights biotech valuation worries—low price, weak volume, and a shaky pipeline prompt investors to question its future.
3 minutes to read